Episode Details

Back to Episodes
ACR2022 - Day 4.1

ACR2022 - Day 4.1

Episode 977 Published 3 years, 6 months ago
Description

Get the Skinny on Bimekizumab in PsA
Dr. Janet Pope discusses abstract presented at ACR22 Convergence in Philadelphia, PA.
L02: Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study

Low dose steroids can negatively impact bone healthDr. Janet Pope discusses abstract L01 presented at ACR22 Convergence in Philadelphia, PA. 
L01: Impact of Glucocorticoid Dosing and Anti-Osteoporotic Treatment on Bone Health in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Longitudinal Cohort Study

The First Head to Head trial in Axial Spondyloarthritis
Dr. Lianne Gensler discusses abstract L15 presented at ACR22 Convergence in Philadelphia, PA.
L15: Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study

Why Clinical Trials?
Dr. Guillermo Valenzuela talks about the importance of clinical trials from ACR22 Convergence in Philadelphia, PA.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us